in 2004, in the case of—
(I)#
a sole source drug shall in no case be less than 88 percent, or exceed 95 percent, of the reference average wholesale price for the drug;
(II)#
an innovator multiple source drug shall in no case exceed 68 percent of the reference average wholesale price for the drug; or
(III)#
a noninnovator multiple source drug shall in no case exceed 46 percent of the reference average wholesale price for the drug;